Bone Abstracts

Background: Long-term use of bisphosphonates has raised concerns about the association with Atypical Femur Fractures (AFFs) that have been reported mainly in postmenopausal women.Clinical case: An 18-year-old patient with juvenile osteoporosis based on X-linked osteoporosis due to a PLS3 mutation developed a low trauma femoral fracture after seven years of intravenous and two years of oral bisphosphonate use, fulfilling the revised ASBMR diagnostic crite...

Epidemiological and experimental data indicates that cadmium creates a risk of bone damage even at low exposure. Our recent findings suggest that this heavy metal may affect bone via destroying the receptor activator of nuclear factor (NF)-κβ (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system balance that plays a key role in the regulation of bone metabolism. The aim of this study was to investigate whether low-level exposure to cadmium, corresponding to low lif...

see PP383....

The clinical orthopaedic problem of delayed healing or non-union after complex fractures affects 5–10% of all patients, especially within the elderly population. Recently several in vitro studies showed that CD133+ cells bare angiogenic capacities and contribute to a better outcome concerning ischemia induced angiogenesis in vivo. A local administration of these specific cells to the fracture gap appears feasible as a new treatment option for biological ...

Bisphosphonates (BPs) such as zoledronic acid (ZA) are widely used to treat bone diseases. The use of BPs can lead to osteonecrosis of the jaw (ONJ), but it is not clear why in particular the jaw bone is affected. Previously, it was shown that osteoclasts derived from different bone sites have different properties. We hypothesize that BPs have distinct effects on bone-site specific osteoclasts or precursors. To investigate this, female C57BL/6J mice were injected intraperitone...

Introduction: Osteoporosis and fragility fractures are recognized complications of rheumatoid arthritis (RA). Previously Riches et al. described a patient with celiac disease and severe osteoporosis in whom neutralizing antibodies to osteoprotegerin (OPG) were present. The aim of this study was to determine if OPG autoantibodies were present in patients with RA and other rheumatic diseases and to relate these to clinical features.Methods: We dev...

Thalassemia is a chronic anemia associate with high rates of osteoporosis. To determine how erythropoiesis leads to bone loss in thalassemia, we used the th3/+ thalassemia mouse to study the role of erythropoietin (EPO) and hematopoietic progenitors (HP), since they are both increased in thalassemia.Methods: Bone marrow mesenchymal stem cells (MSCs) cultures and MSC cocultures with various HP from wild type (wt) and th3/+ mice were diff...

Calcium (Ca) and vitamin D nutritional status effects on oral health were evaluated in 85 healthy women aged between 20 and 30 years (24.6±0.4). They attended the first year of the Nutrition Carrier at the Private University (ISALUD, Buenos Aires, Argentine). Usual Ca intake (CaI) was determined by a food-frequency questionnaire that included consumption of dairy products and calcium-enriched foods. Blood samples were obtained in a fasting state in winter: the end of Augu...

Bisphosphonates are the mainstay of medical therapy in the fracturing child with osteoporosis. The majority of the data in children pertains to i.v. pamidronate use in children and adolescents with osteogenesis imperfecta (OI), where pamidronate has been associated with improvements in bone mineral density, cortical thickness, vertebral shape, pain, mobility and height.1 Side-effects of pamidronate including acute phase response to the initial dose and retardation o...

Selective p38α inhibitors have been found to prevent bone loss induced by estrogen deficiency but implicated mechanisms remained to be identified. The p38 MAPK pathway has been suggested to influence bone resorption at different regulatory levels. In osteoblasts, p38α has been reported to be involved in the production of osteoclastogenic interleukin 6 and Rankl in response to various bone-resorptive agents in vitro. Therefore, we investigated whether p38&#94...